Insider Selling: Inogen (INGN) Director Sells $139,820.00 in Stock
Inogen (NASDAQ:INGN) Director Ray Benjamin M. Anderson sold 1,000 shares of Inogen stock in a transaction on Tuesday, April 17th. The shares were sold at an average price of $139.82, for a total value of $139,820.00. Following the completion of the sale, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $139,820. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of NASDAQ:INGN opened at $141.08 on Friday. The firm has a market capitalization of $2,992.87, a PE ratio of 109.36, a price-to-earnings-growth ratio of 3.93 and a beta of 1.03. Inogen has a 52 week low of $78.30 and a 52 week high of $144.05.
Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Tuesday, February 27th. The medical technology company reported $0.31 EPS for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.10. The business had revenue of $63.79 million during the quarter, compared to the consensus estimate of $62.01 million. Inogen had a return on equity of 13.47% and a net margin of 8.42%. analysts expect that Inogen will post 1.6 EPS for the current year.
INGN has been the subject of a number of recent analyst reports. BidaskClub downgraded Inogen from a “hold” rating to a “sell” rating in a research report on Saturday, January 6th. Zacks Investment Research raised Inogen from a “hold” rating to a “buy” rating and set a $128.00 price objective for the company in a research report on Tuesday, January 9th. Piper Jaffray raised Inogen from a “neutral” rating to an “overweight” rating in a research report on Tuesday, February 20th. Finally, Needham & Company LLC lifted their price objective on Inogen from $125.00 to $150.00 and gave the company a “strong-buy” rating in a research report on Wednesday, February 28th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $121.17.
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.